MRK Daiichi ADC lung cancer
In a significant development for oncology therapeutics, Merck & Co. (MRK) and Daiichi Sankyo have received FDA Priority Review for their antibody-drug conjugate (ADC), ifinatamab deruxtecan, targeting extensive-stage small cell lung cancer (ES-SCLC). This regulatory milestone highlights the growing importance of next-generation targeted therapies in treating aggressive cancers with limited options. 🚀 What Is the … Read more